StreetInsider.com News Articles

Progyny (PGNY) PT Raised to $33 at Citizens on CalPERS Selection as Fertility Benefits Partner

Tue, 08 Sep 2026 04:27:56 -0400

Citizens analyst Constantine Davides raised the price target on Progyny (NASDAQ: PGNY) to $33.00 (from $31.00) while maintaining a Market Outperform rating.

The analyst commented, "We understand that CalPERS (the California Public Employees' Retirement System) has selected Progyny (PGNY) as its fertility benefits partner, effective July 1, 2027. CalPERS is the second-largest public purchaser of health benefits in the nation behind only the federal government, securing health benefits for all California state employees, as well as for the employees of ~1.3K public school districts and ~1.5K local agencies. The organization has ~1.5M covered lives enrolled in its health plans; 888K (~60%)

Progyny (PGNY) PT Raised to $33 at Citizens on CalPERS Selection as Fertility Benefits Partner

Tue, 08 Sep 2026 04:27:56 -0400

Citizens analyst Constantine Davides raised the price target on Progyny (NASDAQ: PGNY) to $33.00 (from $31.00) while maintaining a Market Outperform rating.

Progyny (PGNY) Reiterated at Market Outperform by Citizens as Addressable Market Grows

Wed, 02 Sep 2026 04:19:23 -0400

Citizens analyst Constantine Davides reiterated a Market Outperform rating and $31.00 price target on Progyny (NASDAQ: PGNY).

The analyst commented, "The pooled risk, fixed premium offering is expected to expand PGNY's addressable market by 50M lives. While we do not foresee a material contribution from Select in its first year (2027), the company's historical success at scaling its other solutions gives us conviction in the potential for Select to meaningfully ramp over the next several years. We believe Select could generate $130M+ of margin-accretive revenue by 2030, assuming 1% penetration into its addressable market. We have not yet factored a contribution

Progyny (PGNY) PT Raised to $30 at JPMorgan

Fri, 21 Aug 2026 09:31:58 -0400

JPMorgan analyst Lisa Gill raised the price target on Progyny (NASDAQ: PGNY) to $30.00 (from $27.00) while maintaining a Neutral rating.

Wells Fargo Starts Progyny (PGNY) at Overweight

Thu, 20 Aug 2026 04:55:58 -0400

Wells Fargo initiates coverage on Progyny (NASDAQ: PGNY) with a Overweight rating and a price target of $37.00.

For an analyst ratings summary and ratings history on Progyny click here. For more ratings news on Progyny click here.

Shares of Progyny closed at $25.53 yesterday.

Progyny (PGNY) PT Raised to $36 at Truist Securities

Thu, 13 Aug 2026 07:10:44 -0400

Truist Securities analyst Jailendra Singh raised the price target on Progyny (NASDAQ: PGNY) to $36.00 (from $33.00) while maintaining a Buy rating.

Progyny (PGNY) PT Lowered to $30 at Barclays

Wed, 12 Aug 2026 05:26:46 -0400

Barclays analyst Peter Warendorf lowered the price target on Progyny (NASDAQ: PGNY) to $30.00 (from $34.00) while maintaining a Equalweight rating.

Progyny, Inc. to Present at the Canaccord Genuity Annual Growth Conference

Fri, 07 Aug 2026 10:51:00 -0400

NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, today announced that its CEO Pete Anevski will present at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA on Tuesday, August 11, 2026, at 3:30 p.m. ET.

Live audiocasts and replays of the webcasted session will be available in the Events and Presentations section of Progyny’s investor relations website at http://investors.progyny.com.

About Progyny

Progyny (Nasdaq: PGNY) is a global leader in women's health

Progyny, Inc. to Present at the Canaccord Genuity Annual Growth Conference

Fri, 07 Aug 2026 10:51:00 -0400

Live audiocasts and replays of the webcasted session will be available in the Events and Presentations section of Progyny’s investor relations website at http://investors.progyny.com.

About Progyny

Progyny (Nasdaq: PGNY) is a global leader in women's health

Progyny, Inc. to Present at the Canaccord Genuity Annual Growth Conference

Fri, 07 Aug 2026 10:51:00 -0400

Live audiocasts and replays of the webcasted session will be available in the Events and Presentations section of Progyny’s investor relations website at http://investors.progyny.com.

About Progyny

Progyny (Nasdaq: PGNY) is a global leader in women's health

Progyny, Inc. to Present at the Canaccord Genuity Annual Growth Conference

Fri, 07 Aug 2026 10:51:00 -0400

Live audiocasts and replays of the webcasted session will be available in the Events and Presentations section of Progyny’s investor relations website at http://investors.progyny.com.

About Progyny

Progyny (Nasdaq: PGNY) is a global leader in women's health

Form 10-Q Progyny, Inc. For: Jun 30

Fri, 07 Aug 2026 09:01:00 -0400

si-local-file:///var/storage/secattach/20260807/26888303.html

Form 10-Q Progyny, Inc. For: Jun 30

Fri, 07 Aug 2026 09:01:00 -0400

si-local-file:///var/storage/secattach/20260807/26888303.html

Progyny (PGNY) Tops Q2 EPS by 21c; Offers Guidance

Thu, 06 Aug 2026 17:29:12 -0400

Progyny (NASDAQ: PGNY) reported Q2 EPS of $0.55, $0.21 better than the analyst estimate of $0.34. Revenue for the quarter came in at $350.51 million versus the consensus estimate of $348.69 million.

FY2026 Outlook-

Revenue between $1.36 billion to $1.38 billion versus the consensus $1.38 billion.

EPS between $2.04 to $2.10 versus the consensus $2.06.

Q3 2026 Outlook-

Revenue between $335 million to $345 million versus the consensus $350.6 million.

EPS between $0.50 to $0.52 versus the consensus $0.52.

For earnings history and earnings-related data on Progyny (PGNY) click here.

Form 8-K Progyny, Inc. For: Aug 06

Thu, 06 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260806/26883982.html

Form 8-K Progyny, Inc. For: Aug 06

Thu, 06 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260806/26883982.html

Progyny, Inc. Announces Second Quarter 2026 Results

Thu, 06 Aug 2026 16:01:00 -0400

Reports Record Quarterly Revenue, Gross Profit and Adjusted EBITDA
Robust Selling Season Activity Continues to Reflect Strong Demand for Women's Health, Family Building Solutions
Value Returned to Shareholders Through the Repurchase of Over 2 Million Shares Under Current Authorization

NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”), a global leader in women's health and family building solutions, today announced its financial results for the three-month period ended June 30, 2026 (“the second quarter of 2026”), as compared to the three-month period ended June 30, 2025 (“the second

Progyny, Inc. Announces Second Quarter 2026 Results

Thu, 06 Aug 2026 16:01:00 -0400

Progyny, Inc. Announces Second Quarter 2026 Results

Thu, 06 Aug 2026 16:01:00 -0400

Progyny, Inc. Announces Second Quarter 2026 Results

Thu, 06 Aug 2026 16:01:00 -0400

Form SCHEDULE 13G/A Progyny, Inc. Filed by: FMR LLC

Thu, 06 Aug 2026 10:39:00 -0400

si-local-file:///var/storage/secattach/20260806/26881328.html

Form SCHEDULE 13G/A Progyny, Inc. Filed by: FMR LLC

Thu, 06 Aug 2026 10:39:00 -0400

si-local-file:///var/storage/secattach/20260806/26881328.html

Barclays Downgrades Progyny (PGNY) to Equalweight

Tue, 28 Jul 2026 03:36:16 -0400

Barclays analyst Peter Warendorf downgraded Progyny (NASDAQ: PGNY) from Overweight to Equalweight with a price target of $34.00 (from $27.00).

The analyst comments: “Proprietary analysis of website traffic at leading fertility clinics suggests utilization trends could be easing. We analyzed website traffic across 15 of the leading fertility clinics in the country, which we believe is a reasonable proxy for overall fertility utilization. During that process, we found there is a ~75% correlation between website traffic growth (y/y) and average revenue per member (adjusted for the large customer loss). While the analysis is new to us, we would caution against using

Barclays Downgrades Progyny (PGNY) to Equalweight

Tue, 28 Jul 2026 03:36:16 -0400

Barclays analyst Peter Warendorf downgraded Progyny (NASDAQ: PGNY) from Overweight to Equalweight with a price target of $34.00 (from $27.00).

Progyny, Inc. Announces Details for Its Second Quarter 2026 Results Report

Thu, 23 Jul 2026 15:30:00 -0400

NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, will report its financial results for the quarterly period ended June 30, 2026 after the close of the market on Thursday, August 6, 2026.

The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call.

Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the